Product Update (5202U)
October 18 2010 - 2:01AM
UK Regulatory
TIDMHIK
RNS Number : 5202U
Hikma Pharmaceuticals Plc
18 October 2010
Update on Hikma's US Generics Business
London, 18 October 2010 - Hikma Pharmaceuticals PLC (LSE: HIK)
(NASDAQ DUBAI: HIK)("Hikma"), the fast growing multinational
pharmaceutical group, announces that the dispute between West-Ward
Pharmaceutical Corp. Hikma's US agent and wholly-owned subsidiary,
and Mutual Pharmaceutical Company, Inc. relating to the sale of
oral colchicine tablets has been resolved to the parties' mutual
satisfaction. West-Ward has discontinued its sales of oral
colchicine until approval of its New Drug Application by the U.S.
Food and Drug Administration.
Hikma reconfirms its previously stated guidance of at least 20%
revenue growth for its US Generics business for the full year 2010
and continues to expect its core US Generics business to perform
well in 2011.
ENDS
Enquiries
Hikma Pharmaceuticals PLC +44 (0)20 7399 2760
Susan Ringdal, Investor Relations
Director
Financial Dynamics
Ben Atwell +44 (0)20 7269 7242
Julia Phillips +44 (0)20 7269 7187
Matthew Cole
About Hikma
Hikma Pharmaceuticals PLC is a fast growing global
pharmaceutical group focused on developing, manufacturing and
marketing a broad range of both branded and non-branded generic and
in-licensed products. Hikma's operations are conducted through
three businesses: "Branded", "Injectables" and "Generics" based
primarily in the Middle East and North Africa ("MENA") region,
where it is a market leader, the United States and Europe. In 2009,
Hikma achieved revenues of $637 million and profit attributable to
shareholders of $78 million. For news and other information, please
visit www.hikma.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
PRLLFFLIISLDLII
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024